Myelodysplastic Syndrome (MDS) is a complex and often insidious condition that primarily affects the bone marrow and the production of blood cells.

Chronic leukemias are a group of blood cancers characterized by the slow and progressive accumulation of abnormal white blood cells. Among these, Chronic Lymphocytic Leukemia (CLL) and Chronic Myeloid Leukemia (CML) are two distinct types, each with unique features in terms of biology, presentation, and treatment.

Lung cancer involves abnormal cell growth in the lungs, making it a complex disease. It is one of the leading causes of cancer-related deaths worldwide. Understanding the different types of lung cancer cells and the stages of the disease is crucial for diagnosis, treatment planning, and prognosis.

Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. It mainly attacks myeloid cells, which are responsible for producing red blood cells, platelets, and certain types of white blood cells. AML progresses rapidly, interfering with normal blood cell production and crowding out healthy cells in the bone marrow.

Multiple Myeloma, a complex hematologic malignancy affecting plasma cells, prompts a nuanced exploration into the potential for cure and the factors influencing life expectancy.

Pancreatic cancer poses significant challenges in early detection, making the choice of diagnostic tests critical for effective management. Liquid biopsy stands out as one of the most accurate tests for pancreatic cancer.

Breast cancer is a complex and diverse disease with various subtypes that differ in terms of aggressiveness, treatment approaches, and prognosis. Understanding the specific types of breast cancer is crucial for effective diagnosis and tailored treatment plans. We have categorized them from the least aggressive to the most aggressive.

Liquid biopsy has the advantages of being non-invasive, rapid, accurate, and repeatable. It can also overcome the genetic bias of tissue biopsy. ​ It plays a critical role in precision diagnosis and treatment​.

Minimal Residual Disease (MRD) refers to the tiny traces of cancer cells that may remain in a patient’s body even after treatment has achieved a complete response (CR) in diseases like multiple myeloma (MM).